Stock IMNM IMMUNOME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Company Immunome, Inc.

Equities

IMNM

US45257U1088

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-19 pm EDT 		5-day change 1st Jan Change
15.48 USD -9.90% Intraday chart for Immunome, Inc. -17.88% +44.67%
Apr. 15 Guggenheim Starts Immunome With Buy Rating, $35 Price Target MT
Apr. 01 Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating MT

Business Summary

Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.

Number of employees: 55

Sales per Business

USD in Million2022Weight2023Weight Delta
Biotechnology
100.0 %
0 nan % 14 100.0 % -

Sales per region

USD in Million2022Weight2023Weight Delta
United States
100.0 %
0 nan % 14 100.0 % -

Managers

Managers TitleAgeSince
Clay Siegall CEO
 Chief Executive Officer 64 23-10-01
Max Rosett DFI
 Director of Finance/CFO 34 23-10-01
Bob Lechleider CTO
 Chief Tech/Sci/R&D Officer - 23-10-18
Philip Roberts CTO
 Chief Tech/Sci/R&D Officer - Jan. 03
Jack Higgins CTO
 Chief Tech/Sci/R&D Officer 45 23-10-01
Philip Wagenheim BRD
 Director/Board Member 53 16-12-31
Robert Lapetina AUD
 Comptroller/Controller/Auditor 49 21-04-30
Bruce Turner PRN
 Corporate Officer/Principal 61 23-10-01
Sandra Stoneman LAW
 General Counsel 52 20-12-09
Matthew Robinson PRN
 Corporate Officer/Principal 55 16-02-29

Members of the board

Members of the board TitleAgeSince
Carol Schafer BRD
 Director/Board Member 60 Jan. 01
Jean-Jacques Bienaimé BRD
 Director/Board Member 70 Nov. 06
Clay Siegall CEO
 Chief Executive Officer 64 23-10-01
Philip Wagenheim BRD
 Director/Board Member 53 16-12-31
James Boylan BRD
 Director/Board Member 57 23-10-01
Isaac Barchas BRD
 Director/Board Member 57 23-10-01

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 59,694,243 48,889,289 ( 81.90 %) 0 81.90 %

Shareholders

NameEquities%Valuation
Fidelity Management & Research Co. LLC
7.017 %
3,906,143 7.017 % 96 M $
EcoR1 Capital, LLC
6.969 %
3,879,415 6.969 % 96 M $
Redmile Group LLC
6.969 %
3,879,415 6.969 % 96 M $
Enavate Sciences LP
6.248 %
3,478,261 6.248 % 86 M $
Arsenal Bridge Advisors LLC
4.337 %
2,414,381 4.337 % 60 M $
Vanguard Global Advisers LLC
3.126 %
1,740,026 3.126 % 43 M $
MorphImmune, Inc.
2.799 %
1,558,353 2.799 % 38 M $
Janus Henderson Investors US LLC
2.500 %
1,391,471 2.500 % 34 M $
Avidity Partners Management LP
2.395 %
1,333,479 2.395 % 33 M $
Rapp Rapoport
2.299 %
1,279,914 2.299 % 32 M $

Company contact information

Immunome, Inc.

18702 North Creek Parkway Suite 100

98011, Bothell

+

http://www.immunome.com
address Immunome, Inc.(IMNM)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Bio Therapeutic Drugs

Ratings for Immunome, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
17.18 USD
Average target price
35.33 USD
Spread / Average Target
+105.67%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
IMMUNOME, INC. Stock Immunome, Inc.
+44.67% 1.03B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-3.10% 102B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+2.11% 96.07B
ARGENX SE Stock argenx SE
-1.80% 21.66B
BIONTECH SE Stock BioNTech SE
-17.75% 20.77B
GENMAB A/S Stock Genmab A/S
-6.91% 18.53B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-42.00% 16.91B
BEIGENE, LTD. Stock BeiGene, Ltd.
-28.19% 13.79B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+0.18% 13.33B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+19.90% 10.94B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. IMNM Stock
  4. Company Immunome, Inc.